Mercia EIS Funds

Heiner Dreismann Joins Sense as Chairman

Mercia EIS Funds’ portfolio company, Sense Biodetection Limited (Sense) has announced the appointment of Heiner Dreismann as non-executive Chairman. Heiner was previously the President and CEO of Roche Molecular Systems, the world leader in molecular diagnostics.

During his tenure at Roche Molecular Systems, Heiner oversaw the substantial growth of the PCR business with revenues doubling in five years. In his earlier career at Roche, Heiner led the integration office of the successful acquisition of Boehringer Mannheim into Roche Diagnostics and went on to become Head of Global Business Development with responsibility for the entire diagnostics business.

Commenting on his appointment Heiner said:
“I am delighted to join Sense at this exciting stage in its development and to be in a position to help the company achieve its ambitious plans. Sense has a compelling proposition and a significant opportunity to transform the IVD field with a new class of molecular diagnostic product.”

Sense CEO Harry Lamble commented:
“I am very pleased to welcome Heiner to Sense. I regard Heiner as a pioneer of the molecular diagnostics industry and the whole team is thrilled to have the endorsement of such a global leader in the field. His market insight and wealth of experience will bring great value to the company as we realise our vision of developing the next generation of truly point-of-care molecular tests.”

Heiner has over 35 years experience in the leadership of high growth businesses on a global basis. Since leaving Roche he has served on the board of a number of private and public biotech and healthcare companies.